Journal article
Lenalidomide inhibits the malignant clone and up-regulates the SPARC gene mapping to the commonly deleted region in 5q- syndrome patients.
- Abstract:
-
Myelodysplastic syndromes (MDSs) are a group of hematopoietic stem cell disorders characterized by ineffective hematopoiesis and peripheral blood cytopenias. Lenalidomide has dramatic therapeutic effects in patients with low-risk MDS and a chromosome 5q31 deletion, resulting in complete cytogenetic remission in >60% of patients. The molecular basis of this remarkable drug response is unknown. To gain insight into the molecular targets of lenalidomide we investigated its in vitro effects on...
Expand abstract
- Publication status:
- Published
Actions
Authors
Bibliographic Details
- Journal:
- Proceedings of the National Academy of Sciences of the United States of America
- Volume:
- 104
- Issue:
- 27
- Pages:
- 11406-11411
- Publication date:
- 2007-07-01
- DOI:
- EISSN:
-
1091-6490
- ISSN:
-
0027-8424
- Source identifiers:
-
246233
Item Description
- Language:
- English
- Keywords:
- Pubs id:
-
pubs:246233
- UUID:
-
uuid:0cf7a7e5-2ff0-4626-a234-f1877818f458
- Local pid:
- pubs:246233
- Deposit date:
- 2012-12-19
Terms of use
- Copyright date:
- 2007
If you are the owner of this record, you can report an update to it here: Report update to this record